Jan. 27 at 2:29 PM
$RVTY "Heads up alert! Upcoming earnings on Thursday, 1/29/2026 for
$RVTY
Neutral (5.4)
---
Revvity (RVTY) has demonstrated a complex financial landscape characterized by both promising growth prospects and significant challenges.
The company is currently trading at approximately
$96.77 per share, with a P/E ratio that suggests a valuation reflective of its growth potential, though it has shown only a 2.5% return over the past six months, lagging behind the S&P 500's 13.6% gain.
Analysts anticipate a modest rise in adjusted earnings per share in the upcoming quarter, supported by a robust revenue forecast of around
$772 million for Q4 2025 and approximately
$2.86 billion for the full year.
This aligns with Revvity's strategic initiatives, particularly its recent collaborations with Eli Lilly to enhance AI-driven drug discovery, which could bolster its revenue streams and market position.
Despite these advancements, the company has faced macroeconomic pressures and a mixed performance relative to industry peers in the research tools and consumables sector, where it has underperformed over the past year.
The consensus among analysts remains cautiously optimistic, with expectations for EPS growth and a focus on maintaining competitive advantages in a challenging environment.
---
Looking ahead, Revvity is scheduled to release its fourth-quarter and full-year financial results on February 2, 2026.
Historical performance indicates that the company has a strong track record of exceeding earnings estimates, which could play a crucial role in shaping market sentiment post-announcement.
Analysts are predicting a single-digit increase in adjusted EPS, suggesting that while growth may be modest, it is expected to be consistent with the company's long-term trajectory.
This upcoming report will be pivotal, as it will not only reflect the effectiveness of Revvity's recent strategic initiatives but also provide insights into how well the company is navigating current economic challenges.
---
In terms of sector performance, the healthcare industry, particularly the research tools and consumables segment, has shown resilience despite macroeconomic headwinds.
While Revvity has struggled to keep pace with its peers, there remains a moderate level of optimism regarding its growth trajectory, particularly in light of its innovative AI-driven solutions and strategic partnerships.
As the sector continues to evolve, companies like Revvity that are leveraging technology to enhance drug discovery and development processes are well-positioned to capture market share and drive future growth.
- Funds were net buyers of
$RVTY during the previous reporting quarter.
- Funds with large holdings in
$RVTY include:
- Rgm Capital LLC, MV:
$148MM. Fund Rank: 78%
www.rgmcapital.com
- Primecap Management, MV:
$117MM. Fund Rank: 70%
- Eversept Partners, MV:
$35MM. Fund Rank: 64%
- King Luther Cap, MV:
$10MM. Fund Rank: 75%
- Adage Capital P, MV:
$9MM. New position. Fund Rank: 86%
www.adagecapital.com
- Last 10 days performance: 12%
- Last 30 days performance: 19%
- Last 90 days performance: 20%
Some of the latest news articles:
- Title: Will Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report?
Publication Date: 1/23/2026 5:10:04 PM, Source: yahoo
URL: https://finance.yahoo.com/news/revvity-rvty-beat-estimates-again-171004675.html?.tsrc=rss
- Title: Here's Why You Should Retain Revvity Stock in Your Portfolio for Now
Publication Date: 1/21/2026 12:58:00 PM, Source: yahoo
URL: https://finance.yahoo.com/news/heres-why-retain-revvity-stock-125800699.html?.tsrc=rss
- Title: The Bull Case For Revvity (RVTY) Could Change Following Upbeat 2025 Guidance And New Lilly AI Alliance
Publication Date: 1/14/2026 5:16:08 PM, Source: yahoo
URL: https://finance.yahoo.com/news/bull-case-revvity-rvty-could-171608034.html?.tsrc=rss
- Title: Stocks to Watch Tuesday: JPMorgan, Delta, L3Harris
Publication Date: 1/13/2026 9:23:20 PM, Source: yahoo
URL: https://finance.yahoo.com/m/ded7720e-7fb1-33f6-b33f-95ed9f12d592/stocks-to-watch-tuesday%3A.html?.tsrc=rss
Follow us on stocktwits.com for more earnings alerts. Not a financial advice. Not a trading signal."
